Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors

Clinical and Applied Thrombosis/Hemostasis

Volumn 22, Issue 5, 2016, Pages 423-428

  Beyer, Jacob ^a   Trujillo, Toby ^a   Fisher, Sheila ^b   Ko, Ann ^b   Lind, Stuart E ^c   Kiser, Tyree H ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

anticoagulants; clinical pharmacology; factor Xa inhibitors

Indexed keywords

APIXABAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; CALIBRATION; CHROMOGENIC FACTOR XA ASSAY; CLINICAL ARTICLE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SCREENING; FEMALE; HEMATOLOGY TEST KIT; HUMAN; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RETROSPECTIVE STUDY; STANDARD; STEADY STATE; BLOOD CLOTTING; BLOOD CLOTTING TEST; DOSE RESPONSE; DRUG EFFECTS; EVALUATION STUDY; PROCEDURES; STANDARDS; THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CALIBRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; HEPARIN; HUMANS; PYRAZOLES; PYRIDONES; RIVAROXABAN; THROMBOEMBOLISM;

EID: 84973124396     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616629759     Document Type: Article

References (25)

1. Hillarp A, Gustafsson K, Faxälv L, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost. 2014; 12 (9): 1545-1553.
2. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM,. Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res. 2012; 130 (6): 956-966.
3. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3 (3): 514-521.
4. Samama MM, Martinoli J-L, Leflem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010; 103 (4): 815-825.
5. Francart S, Hawes E, Deal A, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014; 111 (6): 1133-1140.
6. Freyburger G, Macouillard G, Labrouche S, Sztark F,. Coagulation parameters in patients receiving dabigatran or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011; 127 (5): 457-465.
7. Becker RC, Yang H, Barret Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban- an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011; 32 (2); 183-187.
8. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M,. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61 (12): 873-880.
9. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013; 76 (5): 776-786.
10. Cuker A, Siegal D, Crowther M, Garcia D,. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014; 64 (11): 1128-1139.
11. Asmis L, Alberio L, Angelilo-Scherrer A, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res. 2012; 129 (4): 492-498.
12. Samama M, Guinet C, Le Flem L, Ninin E, Debue JM,. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis. 2013; 35 (2): 140-146.
13. Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012; 108 (1): 191-198.
14. Gouin-Thibault I, Flaujac C, Delavenne X, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicenter French GEHT study. Thromb Haemost. 2014; 111 (2): 240-248.
15. Hillarp A, Baghaei F, Fagerber Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011; 9 (1): 133-139.
16. Barrett YC, Wang Z, Frost C, Shenker A,. Clinical laboratory measurement of direct FXa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104 (6): 1263-1271.
17. Gosselin R, Francart S, Hawes E, Moll S, Dager WE, Adcock DM,. Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother. 2015; 49 (7): 777-783.
18. Leil A, Frost C, Wang X, Pfister M, LaCreta F,. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacometrics Syst Pharmacol. 2014; 3: e136.
19. Xarelto: Clinical Pharmacology & Biopharmaceutical Review(s). Food and Drug Administration. 2009. Web site. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022406Orig1s000ClinPharmR.pdf. Accessed October 10, 2015.
20. Reilly P, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014; 63 (4): 321-328.
21. Ruff C, Giugliana R, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385 (9984): 2288-2295.
22. Frost C, Song Y, Barret YC, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 2014; 6: 179-187.
23. Mark C, Vandana M, Michael K, et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors. Blood. 2013; 122 (21): 3636-3636.
24. Laulicht B, Bakhru S, Jiang X, et al. Antidote for New Oral Anticoagulants: Mechanism of Action and Binding Specificity of PER977. Amsterdam, The Netherlands: XXIV Congress of the International Society on Thrombosis and Haemostasis; 2013.
25. Siegal D, Curnutte J, Connolly S, et al. Andexanet Alfa for the reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015; 373 (25): 2413-2424.